QurieGen secures €2.2 million in a pre-seed funding round to develop AI-powered single-cell technology, with backing from Silicon Valley and CEE investors. This funding will accelerate their innovative approach to cancer drug discovery.
Amount Raised
€2.2 Million
Round Type
Pre-Seed
NijmegenBiotechnologyArtificial IntelligenceMachine LearningPharmaceuticalInvestors
Description
QurieGen, a Dutch startup with Polish roots, has raised €2.2 million in a pre-seed round aimed at developing its AI-driven technology for single-cell analysis. Key investors include Tensor Ventures, Lighthouse Ventures, and Tim Draper among others. The company plans to use the funding to enhance its operations and continue research in drug discovery. Their solution addresses the costly and time-consuming challenges faced by pharmaceutical companies in understanding disease mechanisms at the single-cell level.
Who else raised in Pharmaceutical and Biotechnology around the same time
Companies in the same sectors as QurieGen that raised within 45 days of this round, from Fundz verified event records.
Who to call at QurieGen, and when
A new round usually means QurieGen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day QurieGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at QurieGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at QurieGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment QurieGen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
QurieGen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.